HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer's disease in a three cohorts study

Molecular Psychiatry

Volumn 20, Issue 7, 2015, Pages 867-873

  Leduc, V ^a,b   De Beaumont, L ^a   Theroux L ^a   Dea, D ^a   Aisen, P ^c   Petersen, R C ^d   Dufour, R ^b   Poirier, J ^a,e  

^a DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MAYO CLINIC   (United States)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E2; APOLIPOPROTEIN E4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HMGCR PROTEIN, HUMAN;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; EXON SKIPPING; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HETEROZYGOTE; HIPPOCAMPUS; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NORTH AMERICAN; ONSET AGE; PRIORITY JOURNAL; PYROSEQUENCING; RISK ASSESSMENT; RISK REDUCTION; COGNITIVE DEFECT; COHORT ANALYSIS; DISEASE COURSE; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOPHYSIOLOGY; RISK; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL; VERY ELDERLY;

AGE OF ONSET; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; COGNITIVE DYSFUNCTION; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; SEX FACTORS;

EID: 84932196018     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2014.81     Document Type: Article

References (60)

1. Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Hall K, et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol 2008; 7: 812-826
2. Adlard PA, Cummings BJ. Alzheimer's disease-A sum greater than its parts? Neurobiol Aging 2004; 25: 725-733, discussion 743-726
3. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352: 2379-2388
4. Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001; 58: 397-405
5. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1133-1142
6. Petersen RC, Smith GE, Ivnik RJ, Tangalos EG, Schaid DJ, Thibodeau SN, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995; 273: 1274-1278
7. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303-308
8. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 1997; 20: 154-159
9. Gatz M, Fratiglioni L, Johansson B, Berg S, Mortimer JA, Reynolds CA, et al. Complete ascertainment of dementia in the Swedish Twin Registry: the HARMONY study. Neurobiol Aging 2005; 26: 439-447
10. Raiha I, Kaprio J, Koskenvuo M, Rajala T, Sourander L. Alzheimer's disease in twins. Biomed Pharmacother 1997; 51: 101-104
11. Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 2006; 63: 168-174
12. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993; 342: 697-699
13. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al. Apolipoprotein E: high-Avidity binding to beta-Amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993; 90: 1977-1981
14. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-923
15. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43: 1467-1472
16. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell Jr. P.C., et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994; 7: 180-184
17. Benjamin R, Leake A, McArthur FK, Ince PG, Candy JM, Edwardson JA, et al. Protective effect of apoE epsilon 2 in Alzheimer's disease. Lancet 1994; 344: 473
18. de Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-Dglucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci USA 2001; 98: 10966-10971
19. Blacker D, Bertram L, Saunders AJ, Moscarillo TJ, Albert MS, Wiener H, et al. Results of a high-resolution genome screen of 437 Alzheimer's disease families. Hum Mol Genet 2003; 12: 23-32
20. Wollmer MA. Cholesterol-related genes in Alzheimer's disease. Biochim Biophys Acta 2010; 1801: 762-773
21. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011; 43: 429-435
22. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009; 41: 1088-1093
23. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genomewide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009; 41: 1094-1099
24. Bettens K, Sleegers K, Van Broeckhoven C. Current status on Alzheimer disease molecular genetics: from past, to present, to future. Hum Mol Genet 2010; 19: R4-R11
25. Laberge AM, Michaud J, Richter A, Lemyre E, Lambert M, Brais B, et al. Population history and its impact on medical genetics in Quebec. Clin Genet 2005; 68: 287-301
26. Carrasquillo MM, Belbin O, Zou F, Allen M, Ertekin-Taner N, Ansari M, et al. Concordant association of insulin degrading enzyme gene (IDE) variants with IDE mRNA, Abeta, and Alzheimer's disease. PLoS One 2010; 5: e8764
27. Shen L, Kim S, Risacher SL, Nho K, Swaminathan S, West JD, et al. Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: a study of the ADNI cohort. Neuroimage 2010; 53: 1051-1063
28. Poirier J, Apolipoprotein E. cholesterol transport and synthesis in sporadic Alzheimer's disease. Neurobiol Aging 2005; 26: 355-361
29. Yu C, Youmans KL, LaDu MJ. Proposed mechanism for lipoprotein remodelling in the brain. Biochim Biophys Acta 2010; 1801: 819-823
30. Ohm TG, Treiber-Held S, Distl R, Glockner F, Schonheit B, Tamanai M, et al. Cholesterol and tau protein-findings in Alzheimer's and Niemann Pick C's disease. Pharmacopsychiatry 2003; 36: S120-S126
31. Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997; 349: 151-154
32. Marchant NL, Reed BR, Sanossian N, Madison CM, Kriger S, Dhada R, et al. The aging brain and cognition: contribution of vascular injury and abeta to mild cognitive dysfunction. JAMA Neurol 2013; 70: 488-495
33. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000; 356: 1627-1631
34. Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in communitydwelling elderly people. Arch Neurol 2002; 59: 223-227
35. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57: 1439-1443
36. Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med 2007; 5: 20
37. Riekse RG, Li G, Petrie EC, Leverenz JB, Vavrek D, Vuletic S, et al. Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. J Alzheimers Dis 2006; 10: 399-406
38. Li G, Larson EB, Sonnen JA, Shofer JB, Petrie EC, Schantz A, et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 2007; 69: 878-885
39. Kehoe P, Wavrant-De Vrieze F, Crook R, Wu WS, Holmans P, Fenton I, et al A full genome scan for late onset Alzheimer's disease. Hum Mol Genet 1999; 8: 237-245
40. Porcellini E, Calabrese E, Guerini F, Govoni M, Chiappelli M, Tumini E, et al. The hydroxy-methyl-glutaryl CoA reductase promoter polymorphism is associated with Alzheimer's risk and cognitive deterioration. Neurosci Lett 2007; 416: 66-70
41. Rodriguez-Rodriguez E, Mateo I, Infante J, Llorca J, Garcia-Gorostiaga I, Vazquez-Higuera JL, et al. Interaction between HMGCR and ABCA1 cholesterol-related genes modulates Alzheimer's disease risk. Brain Res 2009; 1280: 166-171
42. Wollmer MA, Sleegers K, Ingelsson M, Zekanowski C, Brouwers N, Maruszak A, et al. Association study of cholesterol-related genes in Alzheimer's disease. Neurogenetics 2007; 8: 179-188
43. Medina MW, Gao F, Ruan W, Rotter JI, Krauss RM. Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma lowdensity lipoprotein cholesterol response to simvastatin. Circulation 2008; 118: 355-362
44. Burkhardt R, Kenny EE, Lowe JK, Birkeland A, Josowitz R, Noel M, et al. Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13. Arterioscler Thromb Vasc Biol 2008; 28: 2078-2084
45. Yu CY, Theusch E, Lo K, Mangravite LM, Naidoo D, Kutilova M, et al. HNRNPA1 regulates HMGCR alternative splicing and modulates cellular cholesterol metabolism. Hum Mol Genet 2013; 23: 319-332
46. Aulchenko YS, Ripatti S, Lindqvist I, Boomsma D, Heid IM, Pramstaller PP, et al. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet 2009; 41: 47-55
47. Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton Jr. V.P., Ridker PM. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 2004; 291: 2821-2827
48. Krauss RM, Mangravite LM, Smith JD, Medina MW, Wang D, Guo X, et al. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation 2008; 117: 1537-1544
49. Dea, D Théroux, L. Legault, V. Leduc, V. Poirier, J. HMG-COA reductase as a risk factor and modulator of Alzheimer pathology. 11th International Conference of Alzheimers Disease and Related Disorders; 2010. Hawai, USA: Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2010) S191
50. Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985; 42: 1097-1105
51. Gagnon A, Toupance B, Tremblay M, Beise J, Heyer E. Transmission of migration propensity increases genetic divergence between populations. Am J Phys Anthropol 2006; 129: 630-636
52. Betard C, Kessling AM, Roy M, Chamberland A, Lussier-Cacan S, Davignon J. Molecular genetic evidence for a founder effect in familial hypercholesterolemia among French Canadians. Hum Genet 1992; 88: 529-536
53. Royo JL, Hidalgo M, Ruiz A. Pyrosequencing protocol using a universal biotinylated primer for mutation detection and SNP genotyping. Nat Protoc 2007; 2: 1734-1739
54. Li G, Higdon R, Kukull WA, Peskind E, Van Valen Moore K, Tsuang D, et al. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 2004; 63: 1624-1628
55. Rea TD, Breitner JC, Psaty BM, Fitzpatrick AL, Lopez OL, Newman AB, et al. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol 2005; 62: 1047-1051
56. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 2009; 80: 13-17
57. Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease. LEADe. Neurology 2010; 74: 956-964
58. Arvanitakis Z, Knopman DS. Clinical trial efforts in Alzheimer disease. Why test statins? Neurology 2010; 74: 945-946
59. Keller L, Murphy C, Wang HX, Fratiglioni L, Olin M, Gafvels M, et al A functional polymorphism in the HMGCR promoter affects transcriptional activity but not the risk for Alzheimer disease in Swedish populations. Brain Res 2010; 1344: 185-191
60. Bettermann K, Arnold AM, Williamson J, Rapp S, Sink K, Toole JF, et al. Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study. J Stroke Cerebrovasc Dis 2011; 21: 436-444